en عمومى General مروری Review Article <span style="font-size:12pt"><span style="line-height:16.0pt"><span new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt">The severe acute respiratory syndrome coronavirus 2 (known as COVID-19), initially appeared in the Wuhan city of China in December 2019, has become a current medical issue around the world. Due to its highly contagious nature, COVID-19 has spread widely to all countries. As no effective treatment or vaccine is developed for this infectious disease, preventive measures are the only mandatory strategy to stop its human-to-human transmission. In the present spread of COVID-19, the discovery of antiviral drugs is crucially important as the development of these drugs often takes time. However, no specific drug has yet been approved for COVID-19. In this review, we focus on the available drug candidates used for the treatment of infections caused by COVID-19 to identify potential inhibitors through molecular docking.</span></span></span></span> Antiviral drug, COVID-19, Inhibitors, Molecular docking, SARS COV-2 89 106 http://hsm.umsu.ac.ir/browse.php?a_code=A-10-85-1&slc_lang=en&sid=1 Aynaz Nourani aynaz.nourani@gmail.com 10031947532846001514 10031947532846001514 No Department of Health Information Technology, School of Allied Medical Sciences, Urmia University of Medical Sciences, Urmia, Iran Vahid Rahimkhoei vahidrahimkhoei@gmail.com 10031947532846001515 1111-1111-1111-1111 No Solid Tumor Research Center, Research Institute for Cellular and Molecular Medicine, Urmia University of Medical Sciences, Urmia, Iran Ali Akbari akbari.a@umsu.ac.ir 10031947532846001516 1111-1111-1111-1111 Yes Solid Tumor Research Center, Research Institute for Cellular and Molecular Medicine, Urmia University of Medical Sciences, Urmia, Iran